OneDigital Investment Advisors LLC Has $3.22 Million Position in Insulet Corporation (NASDAQ:PODD)

OneDigital Investment Advisors LLC lifted its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 260.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,265 shares of the medical instruments supplier's stock after acquiring an additional 8,867 shares during the period. OneDigital Investment Advisors LLC's holdings in Insulet were worth $3,221,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Horizon Investments LLC boosted its position in shares of Insulet by 3.1% in the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock worth $362,000 after buying an additional 42 shares during the period. Envestnet Portfolio Solutions Inc. boosted its holdings in Insulet by 2.3% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock worth $552,000 after acquiring an additional 48 shares during the period. Steward Partners Investment Advisory LLC grew its position in Insulet by 5.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock valued at $274,000 after acquiring an additional 50 shares in the last quarter. Sequoia Financial Advisors LLC raised its stake in shares of Insulet by 2.4% during the fourth quarter. Sequoia Financial Advisors LLC now owns 2,170 shares of the medical instruments supplier's stock valued at $566,000 after purchasing an additional 50 shares during the period. Finally, Quadrant Capital Group LLC boosted its stake in shares of Insulet by 4.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,092 shares of the medical instruments supplier's stock valued at $285,000 after purchasing an additional 51 shares during the period.

Analysts Set New Price Targets

PODD has been the topic of a number of analyst reports. The Goldman Sachs Group started coverage on Insulet in a research report on Friday, May 30th. They set a "buy" rating and a $380.00 target price on the stock. Oppenheimer lifted their price target on shares of Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Wall Street Zen downgraded shares of Insulet from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. Raymond James Financial reiterated an "outperform" rating and issued a $360.00 price target (up from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Finally, Wells Fargo & Company set a $322.00 target price on Insulet in a report on Monday, April 28th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $321.00.

Insider Buying and Selling at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the sale, the senior vice president directly owned 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.39% of the stock is currently owned by corporate insiders.

Insulet Price Performance

Shares of PODD stock traded down $0.35 during mid-day trading on Monday, hitting $300.70. 585,441 shares of the stock traded hands, compared to its average volume of 720,244. Insulet Corporation has a twelve month low of $173.00 and a twelve month high of $329.33. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.63 and a current ratio of 4.47. The company's 50-day simple moving average is $303.07 and its 200-day simple moving average is $279.13. The firm has a market cap of $21.16 billion, a price-to-earnings ratio of 54.08, a price-to-earnings-growth ratio of 2.69 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The company had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 18.29% and a return on equity of 22.25%. Insulet's revenue was up 28.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.73 EPS. As a group, equities research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.